This document analyzes prescription habits of pediatricians in India for various respiratory medications. It finds that cough is the most prevalent childhood illness, with bronchodilators being the most commonly prescribed molecule. Pediatricians prefer flavors like mint and mixed fruits for cough preparations. Nasal decongestants make up 88% of prescriptions for nasal congestion, with xylometazoline being the leading molecule. Respules are prescribed routinely by 30% of doctors, with salbutamol/levosalbutamol being the preferred molecule for nebulization. The document provides market share data for leading respiratory medication brands prescribed by pediatricians.

1. Presented by:
Deepak Sahu
(PGDPM)
IIHMR Jaipur

2. Aim of project:
o To study & analyze the prescription habit of pediatrician
for cough preparation.
o To find out the mostly prescribed nasal decongestant by
pediatrician.
o To study & analyze the prescription pattern for respules.
o Make the therapy map for children.

3. Research Methodology
 Data source
primary data source.
 Research approach
descriptive survey research
 Research instruments
Questionnaires (multiple choice-closed ended and open ended
questions)
 Sampling plan
a. Sampling unit:
b. Sample size:
c. Sampling procedures:

Contact method
Personal Interview
Pediatrician & Chemist
50 pediatrician & 30 chemist
simple random sampling

4. Areas covered during survey
S.No
Area covered
No. Of Doctor
No. of chemist
1
Sion
3
3
2
Villey parle
3
2
3
Gathkopar
4
3
4
Kalyan
5
4
5
Ullash nagar
3
1
6
Karla
5
4
7
Goregoan
4
3
8
Mulund
6
4
9
Bhandup
8
4
10
Bandra
4
11
Vashi
5
12
Marine line
1
13
Charni road
1
2

5. Objective:
To analyze how Paediatrician select the
different combinations of cough preparation.

6. Analysis :
Prevalence of cough in children
2%
16%
(0-5)
(5-10)
(10-15)
54%
20- more
28%

7. Parameters for Selection of cough Preparations
10%
6%
2%
8%
8%
Dose,molecule & Taste
Clinical Study
Platability, Safety & Side effect
Cough History
Cough Type
Cause & Sine
66%

8. Preferred molecule
4%
40%
bronchodilator
mucolytic
suppressant & bronchodialator
other
54%
2%

9. Preferred flavor
22%
30%
Mint
Strawberry
mixed Fruit
orange
14%
34%
Not specific

10. Preferred parameter
18%
Flavour
4%
Pack size
2%
recommendation
52%
14%
Dosage titration
Dosage form
Price
Other
8%
2%

11. Finding & suggestions:
 Prevalence of cough in children is more then other





disease.
Basic parameters are cough type, cough history & cause.
Most preferred molecule is Bronchodilator ,then
suppressant.
Majority of pediatrician preferred mixed fruits flavor &
they are looking for palatability.
Basic parameter while choosing any cough preparation
are palatability, dose titration & pack size, then later on
company & fso.
We should organize some camp at dr. clinic for patient
eduction.

12. To find out the mostly prescribed
nasal decongestant by pediatrician.
No. Of patient
8%
8%
38%
10%
(0-5)
(5-10)
(10-15)
(15-20)
14%
20<
Occasionally
22%

13. Preferred molecule
4%
8%
Normal Saline
oxymethazone
Xylomethazoline
88%

14. Finding & suggestion:
 40% of children with urti having nasal congestion.
 Majority of Dr. having patient with nasal congetion.
 Nasal congestion is the marketing driving molecule.
 It takes 88% market share as per Rx wise.
 But Xylometazoline & oxymetazoline are market follwing
molecule.
 This is another huge market for us to expanding the
pediatric basket.

15. To study uses of respiratory solution in
children
% of preference
8%
Yes
no
92%

16. No. of patients
14%
30%
(1-10)
14%
(10-20)
(20-30)
30-above
seasonal
12%
30%

17. Dr. preference to keep stock
42%
Yes
58%
No

18. Preferred molecule
16%
8%
Salbutamol/ levosalbutamol
Ipratropium
Budisonide
Comb
14%
62%

19. % Dr prefer inhalation
28%
yes
No
72%

20. Market leader:
S.No
1.
Company
Cipla
Brand
Schemed
Percentage
Astahlin
16+4
25
Duolin
18+2
10
Levolin
21+4
20

21. Finding & suggestions:
 92 % pediatrician prefer nebulization.
 30 % of doctor prescribe respules on his routine practice.
 58% of doctors are keeping stock of respules in his clinic
or nursing home .
 62% of Dr. prefer salbutamol & levosalbutamol as first
choice for nebulization.
 92% of market share is own by Cipla.

22. Therapy map for children

23. Demographic indicator:
 Population: 1,029,991,145 (July 2001 EST.)
 Age structure:
-(0-14) years: 33.12%
(male 175,630,537; female 165,540,672)
-(15-64 )years: 62.2%
(male 331,790,850; female 308,902,864)
 Birth rate:
24.28 births/1,000 population (2001 EST.)

26. Indication
Total
Rx-Jan MAT Rx-Jan MAT
09
10
Rx Grth
120,660
126,757
5
26,147
28,351
8
Diarrhea / Gastroenteritis
14,674
15,447
5
Lower respiratory infection
14,622
15,423
5
Fever
9,130
9,306
2
Viral infection
5,052
6,326
25
Bronchitis
4,450
4,918
11
Respiratory tract infection
2,971
2,650
-11
Acute Pharyngitis
2,810
2,645
-6
Chronic rhinitis / Pharyngitis
1,761
2,317
32
Asthma
2,340
2,261
-3
Abdominal and pelvic pain
2,029
2,175
7
Common cold
2,039
1,901
-7
Cough
1,857
1,876
1
Routine child health examination
1,790
1,822
2
Gastritis and duodenitis
1,640
1,792
9
Acute Respiratory tract infection

28. Avg
DrsMAT
Jan 09
Specialty
Rx-MAT
Jan 09
Rx-MAT
Jan 10
Rx
Grth
%
Avg DrsMAT Jan
10
Rxer
Grth
Dispersion
P/D-Mar
Mat'10
All Doctors
1,493,927
1,576,544
6
228,645
239,579
5
100
548
G.P.(Non MBBS)
382,355
408,611
7
59,646
63,053
6
26.4
540
G.P.(MBBS)
219,344
220,291
0
30,076
29,806
-1
12.3
618
Consulting Physician
129,526
137,582
6
16,590
17,540
6
7.3
655
Dentist
128,010
136,903
7
24,867
26,774
8
11.2
427
Pediatrician
120,660
126,757
5
14,068
14,698
4
6.1
720
Gynecologist
116,450
123,236
6
21,194
21,882
3
9.1
470
Gen.Surgeon
63,176
67,019
6
9,837
10,105
3
4.2
552
Orthopaedic
57,897
62,445
8
9,280
9,845
6
4.1
527
Ophthalmologist
61,211
62,039
1
9,151
9,511
4
4.0
542
ENT Specialist
42,198
45,240
7
6,336
6,643
5
2.8
570
Cardiologist
35,505
38,267
8
5,287
5,611
6
2.3
569
Dermatologist
29,887
31,428
5
4,533
4,739
5
2.0
554
Chest TB Specialist
25,723
28,246
10
3,470
3,776
9
1.6
623
Neurologist Neuro Surgeon
19,049
21,023
10
3,329
3,666
10
1.5
478
Nephrologist Urologist
15,493
16,865
9
2,866
3,074
7
1.3
457
Diabetologist Endocrinologist
13,520
14,803
9
2,204
2,487
13
1.1
493
Psychiatrist
14,048
14,709
5
2,315
2,425
5
1.0
508
Gastroenterologist
13,007
14,167
9
2,241
2,466
10
1.0
475
Oncologist
6,867
6,912
1
1,356
1,481
9
0.6
384

29. Speciality
9 95 9 1
10 10
5
10
0
1 1 11
8
2 2
2
7
3
1
G.P.(Non MBBS)
G.P.(MBBS)
7
26
Dentist
4
8
Consulting Physician
Paediatrician
Gynaecologist
4
Gen.Surgeon
6
Orthopaedic
4
Ophthalmologist
ENT Specialist
6
8
Cardiologist
14
Dermatologist
0
8
5
9
7
Chest TB Specialist
Neurologist Neuro Surgeon
9
Nephrologist Urologist
6
Diabetologist Endocrinologist
Psychiatrist

31. Rx'000-Mar Mat'09
Rx'000PrescriptionsMar Mat'10
Rx Grth
P/D-10
Peaadiatric
121,831
127,738
5
720
Anti-Infective
63,835
66,163
4
374
Respiratory
55,613
59,196
6
335
Pain / Analgesics
46,465
49,547
7
281
Others
43,078
45,692
6
261
Gastro Intestinal
31,773
33,842
7
192
Vitamins / Minerals / Nutrients
19,405
19,926
3
115
Derma
8,380
8,421
0
50
Anti-Parasitic
8,180
7,592
-7
47
Hormones
5,495
5,656
3
45
Gynaec.
4,297
4,559
6
31
Neuro / CNS
3,106
3,218
4
23
Anti-Malarials
3,083
2,808
-9
35
Ophthal / Otologicals
2,822
2,725
-3
19
Therapy

32. Acid peptic disease / Acidity / Hyperacidity
Conjunctivitis
Constipation
Chronic sinusitis
Urticaria
Skin infection
Anorexia
Typhoid and paratyphoid fevers
Otitis media
Dehydration
Injury
COPD
Boil / Abscess
Wheezing
Malaria
Acute tonsillitis
Acute bronchitis
UTI
Helminthiases
Anaemia
Nausea and vomiting
immunization
Weakness / Malaise and fatigue
Gastritis and duodenitis
Routine child health examination
Cough
Common cold
Abdominal and pelvic pain
Asthma
Chronic URTI
Acute pharyngitis
RTI
Bronchitis
Viral infection
Fever
LRTI
Diarrhoea / Gastroenteritis
Acute URTI
30,000
25,000
20,000
15,000
10,000
5,000
Series1
0
Series2

33. N 2B NON-NARCOTICS,ANTIPYER.
J 1D CEPHALOSPORINS
R 5B COUGH PREPARATIONS
M 1A ANTIRHEUMATIC NONSTR.
J 1C AMPICILLIN AMOXYCILLIN
R 5A COLD PREPARATIONS
R 6A ANTIHISTAMINES,SYSTEMIC
J 1F MACROLIDES AND SIMILAR
R 3E BRONCHODILATORS LIQUIDS
J 1L QUINOLONES
A 7K OTH.INCL.LACTIC FERMENT
R 1A NASAL DECONGESTANTS
A 7L ORAL ELECTROLYTES
A 4D ANTIEMET.,ANTINAUS LIQ.
A11A MULTIVIT.WITH MINERALS
H 2A SYS.CORTICOSTEROIDS PL.
A11E VITAMIN B COMPLEX
A 2B ANTIPEPTIC ULCERANTS
P 1B ANTHELMINTICS EX.SCHIS.
A 7G OFLOXACIN COMB.
A 3C ANTISPASM.ANTICHOL. COMB.
B 3A HAEMATINICS,IRON+COMB
A 4C ANTIEMET.,ANTINAUS SOL.
A 2A ANTACID,ANTIFLATULENTS
A 9A DIGESTIVES INC.ENZYMES
P 1D ANTIMALARIALS
R 3C BRONCHODIL.INHALANT PREP.
A12A CALCIUM PREP.
D 6A TOP.ANTIBIOTICS PLAIN
J 1K ALL OTHER ANTIBIOTICS
R 3D BRONCHODILATORS SOLIDS
A 7B NORFLOXACIN COMB.
P 1A AMOEBICIDES
A11B MULTVIT.WITHOUT MINERALS
N 5B TRANQUILIZERS
A12C OTHER MINERAL SUPPLEMENT
A15A APPETITE STIMULANTS
D 2A EMOLLIENTS,PROTECTIVES
A 7M OTHER ANTIDIARRHOEALS
J 7A PAEDIATRIC SINGLE VACCINE
A 5B HEPATIC PROT.LIPOTROPIC
S 1A ANTIINFECTIVES
J 1E TRIMETHOPRIM COMB.& SIMI.
S 2A OTOLOGICALS
A 7A PLAIN INTEST.ANTIINFECT.
A 4F ANTIEMET.,ANTINAUS COMB.
35,000
30,000
25,000
20,000
15,000
10,000
5,000
0

34. 25,000
Major Player
20,000
15,000
10,000
Series1
Series2
5,000
0

35. Market driving molecules:
30,000
25,000
20,000
15,000
10,000
Series1
5,000
0
Series2

36. Top 20molecule with growing trend

37. S.n
o
Subgroup
1
Cepodoxime oral liq.
11147
33
2
Cefixime oral solid
52945
3
Cefpodoxime oral solid
4
MAT Mar 10
Value Grth
Unit Grth
(Value)
(MAT Mar 10) (MAT Mar 10)
Rx share%
RX Grw%
P/D Rx
33
16
7
41
23
29
13
11
35
27429
32
31
13
18
39
Cefixime oral liq.
9235
15
22
10
21
28
5
Cefadroxil oral liq.
2052
-1
-2
7
-21
24
6
Cefadroxil oral solid
13248
-8
0
6
-9
24
7
Amoxy & Clav.liq
15270
33
41
40
16
53
8
Amoxy & Clav.solid
36532
35
52
17
27
31
9
Amoxy solid
24106
10
-4
15
-5
36
10
Amoxy liq
6639
7
-1
13
-8
35
11
Azithromycin oral liq
31650
28
26
47
9
44
12
Azithromycin oral solid
5623
44
36
31
34
32
13
Erythromycin Liq
2360
14
16
5
10
17
14
Erythromycinoral solid
7406
7
9
5
-18
16

38. S.n
o
Subgroup
15
MAT Mar 10
Value Grth Unit Grth (MAT
(Value)
(MAT Mar 10)
Mar 10)
Rx share%
RX Grw%
P/D Rx
RANITIDINE ORAL
SOLIDS
24528
12
-5
18
11
16
LANSOPRAZOLE
2016
14
2
15
36
19
PANTOPR.+
DOMPERID.
17763
33
26
10
91
22
PANTOPRAZOLE
SOLIDS
18948
20
15
9
55
13
ORAL
ELECTROLYTES
14597
27
17
85
10
48
Nasal Decongestant
13592
30
22
13
8
55
16
17
18
19
20

39. Thank You